These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 17889135

  • 1. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
    Sánchez Fructuoso A, Calvo N, Moreno MA, Giorgi M, Conesa J, Barrientos A.
    Transplant Proc; 2007 Sep; 39(7):2194-6. PubMed ID: 17889135
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Bilodeau JF, Montambault P, Wolff JL, Lemire J, Masse M.
    Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
    [Abstract] [Full Text] [Related]

  • 3. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
    Budde K, Glander P, Diekmann F, Dragun D, Waiser J, Fritsche L, Neumayer HH.
    Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
    [Abstract] [Full Text] [Related]

  • 4. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
    Ortega F, Sánchez-Fructuoso A, Cruzado JM, Gómez-Alamillo JC, Alarcón A, Pallardó L, Morales JM, Oliver J, Guinea G, MYVIDA Study Group.
    Transplantation; 2011 Aug 27; 92(4):426-32. PubMed ID: 21760569
    [Abstract] [Full Text] [Related]

  • 5. Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: conversion to enteric-coated mycophenolate sodium.
    Calvo N, Sanchez-Fructuoso AI, Conesa J, Moreno A, Barrientos A.
    Transplant Proc; 2006 Oct 27; 38(8):2396-7. PubMed ID: 17097945
    [Abstract] [Full Text] [Related]

  • 6. Use of mycophenolate sodium in stable renal transplant recipients in Spain: preliminary results of the MIDATA study.
    Sánchez-Fructuoso A, Ruiz JC, Rengel M, Andrés A, Morales JM, Beneyto I, Guirado LI, Cantarell C, Epi-trasplante Study, MIDATA Sub-Study Group.
    Transplant Proc; 2009 Oct 27; 41(6):2309-12. PubMed ID: 19715904
    [Abstract] [Full Text] [Related]

  • 7. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients.
    Sollinger H.
    Transplant Proc; 2004 Mar 27; 36(2 Suppl):517S-520S. PubMed ID: 15041399
    [Abstract] [Full Text] [Related]

  • 8. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects.
    Sabbatini M, Capone D, Gallo R, Pisani A, Polichetti G, Tarantino G, Gentile A, Rotaia E, Federico S.
    Fundam Clin Pharmacol; 2009 Oct 27; 23(5):617-24. PubMed ID: 19656208
    [Abstract] [Full Text] [Related]

  • 9. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China.
    Xu L, Cai M, Shi BY, Li ZL, Li X, Jin HL.
    Transplant Proc; 2014 Jun 27; 46(5):1362-5. PubMed ID: 24935300
    [Abstract] [Full Text] [Related]

  • 10. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study.
    Langone AJ, Chan L, Bolin P, Cooper M.
    Transplantation; 2011 Feb 27; 91(4):470-8. PubMed ID: 21245794
    [Abstract] [Full Text] [Related]

  • 11. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
    Massari P, Duro-Garcia V, Girón F, Hernández E, Juárez F, Castro C, Toledo M, myPROMS LatAm Study Group.
    Transplant Proc; 2005 Mar 27; 37(2):916-9. PubMed ID: 15848574
    [Abstract] [Full Text] [Related]

  • 12. Use of enteric-coated mycophenolate sodium in liver transplant patients with intestinal intolerance caused by mycophenolate mofetil.
    Doria C, Ramirez CB, Frank AM, Vaccino S, Fraser N, Marino IR.
    Clin Transplant; 2009 Mar 27; 23(6):882-6. PubMed ID: 19573090
    [Abstract] [Full Text] [Related]

  • 13. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders.
    Darji P, Vijayaraghavan R, Thiagarajan CM, Sharma RK, Subbarao B, Pishardy R, Dakshinamurthy KV, Vijaykumar R, Abraham G, Bhaskar S, Agarwal L, Shah B, Abraham A, John M, Sampathkumar K, Das T, Umesh L, Sundar S, Ballal H, Jasuja S, Saxena S, Saha TK.
    Transplant Proc; 2008 Sep 27; 40(7):2262-7. PubMed ID: 18790208
    [Abstract] [Full Text] [Related]

  • 14. Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients.
    Burg M, Säemann MD, Wieser C, Kramer S, Fischer W, Lhotta K.
    Transplant Proc; 2009 Dec 27; 41(10):4159-64. PubMed ID: 20005359
    [Abstract] [Full Text] [Related]

  • 15. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K, Glander P, Krämer BK, Fischer W, Hoffmann U, Bauer S, Grohmann J, Neumayer HH, Arns W.
    Transplantation; 2007 Feb 27; 83(4):417-24. PubMed ID: 17318074
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus.
    Hwang HS, Hyoung BJ, Kim S, Oh HY, Kim YS, Kim JK, Kim YH, Kim YL, Kim CD, Shin GT, Yang CW.
    J Korean Med Sci; 2010 Dec 27; 25(12):1759-65. PubMed ID: 21165291
    [Abstract] [Full Text] [Related]

  • 18. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil.
    Arns W, Breuer S, Choudhury S, Taccard G, Lee J, Binder V, Roettele J, Schmouder R.
    Clin Transplant; 2005 Apr 27; 19(2):199-206. PubMed ID: 15740555
    [Abstract] [Full Text] [Related]

  • 19. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
    Salvadori M, Bertoni E, Budde K, Holzer H, Civati G, Lien B, Arns W.
    Transplant Proc; 2010 May 27; 42(4):1325-8. PubMed ID: 20534293
    [Abstract] [Full Text] [Related]

  • 20. The Cost of Gastrointestinal Adverse Events and the Impact of Dose-Reductions/Discontinuations on Acute Rejection in Kidney Transplant Patients of Mycophenolate Mofetil-Related Compared to Enteric-Coated Mycophenolate Sodium: A Pharmacoeconomic Study.
    Martinez-Mier G, Salazar-Ramirez A.
    Transplant Proc; 2016 Mar 27; 48(2):588-95. PubMed ID: 27110009
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.